Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 168

1.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M.

Clin Microbiol Infect. 2018 Feb 12. pii: S1198-743X(18)30150-2. doi: 10.1016/j.cmi.2018.02.002. [Epub ahead of print] Review.

PMID:
29447987
2.

Comparative Effectiveness of Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30213-5. doi: 10.1016/j.jaad.2018.02.027. [Epub ahead of print] Review.

PMID:
29438757
3.

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.

Frieder J, Kivelevitch D, Menter A.

Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16. Review.

4.

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. Review.

PMID:
29332708
5.

Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018. Review.

6.

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.

Kawalec P, Holko P, Moćko P, Pilc A.

Rheumatol Int. 2018 Feb;38(2):189-201. doi: 10.1007/s00296-017-3919-7. Epub 2017 Dec 28. Review.

7.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2. Review.

PMID:
29271481
8.

A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.

Hu Y, Chen Z, Gong Y, Shi Y.

Clin Drug Investig. 2017 Dec 16. doi: 10.1007/s40261-017-0603-3. [Epub ahead of print] Review.

PMID:
29249053
9.

Safety of biologics in psoriasis.

Kamata M, Tada Y.

J Dermatol. 2017 Dec 10. doi: 10.1111/1346-8138.14096. [Epub ahead of print] Review.

PMID:
29226369
10.

Secukinumab (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Mar 10.

11.

Secukinumab: Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Aug 28.

12.

Secukinumab (Addendum to Commission A15-20) [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Oct 28.

13.

Treatment Approaches to Moderate to Severe Psoriasis.

Gisondi P, Del Giglio M, Girolomoni G.

Int J Mol Sci. 2017 Nov 16;18(11). pii: E2427. doi: 10.3390/ijms18112427. Review.

14.

The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.

Sanchez IM, Sorenson E, Levin E, Liao W.

Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15. Review.

15.

Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.

Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, Bottiglieri P, Scarpa R, Caso F.

Drugs R D. 2017 Dec;17(4):509-522. doi: 10.1007/s40268-017-0215-7. Review.

16.

Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.

Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E.

Am J Clin Dermatol. 2017 Sep 18. doi: 10.1007/s40257-017-0322-9. [Epub ahead of print] Review.

PMID:
28921458
17.

Psoriasis pathogenesis and the development of novel targeted immune therapies.

Hawkes JE, Chan TC, Krueger JG.

J Allergy Clin Immunol. 2017 Sep;140(3):645-653. doi: 10.1016/j.jaci.2017.07.004. Review.

PMID:
28887948
18.

A Review of the Use of Secukinumab for Psoriatic Arthritis.

Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR.

Rheumatol Ther. 2017 Dec;4(2):233-246. doi: 10.1007/s40744-017-0076-0. Epub 2017 Aug 28. Review.

19.

Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.

Rios Rodriguez V, Poddubnyy D.

Ther Adv Musculoskelet Dis. 2017 Aug;9(8):197-210. doi: 10.1177/1759720X17706454. Epub 2017 May 9. Review.

20.

Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.

Balato A, Scala E, Balato N, Caiazzo G, Di Caprio R, Monfrecola G, Raimondo A, Lembo S, Ayala F.

Expert Opin Biol Ther. 2017 Nov;17(11):1363-1374. doi: 10.1080/14712598.2017.1363884. Epub 2017 Aug 9. Review.

PMID:
28791896

Supplemental Content

Loading ...
Support Center